# Efficacy of Thymosin Alpha-1 in Combination Therapy for Hepatocellular Carcinoma

Canonical source: https://retacompare.com/research/efficacy-of-thymosin-alpha-1-in-combination-therapy-for-hepatocellular-carcinoma

Immune & Anti-inflammatory · 2025-04-22


    Thymosin Alpha-1 combined with lenvatinib and sintilimab demonstrates improved survival outcomes in patients with unresectable hepatocellular carcinoma. This combination therapy has shown promise in enhancing overall and progression-free survival rates compared to standard treatment regimens. The findings support the potential role of Thymosin Alpha-1 in therapeutic strategies for this challenging cancer type.

 What this study examined

This retrospective study analyzed the efficacy and safety of Thymosin Alpha-1 when used in conjunction with lenvatinib and sintilimab in patients diagnosed with unresectable hepatocellular carcinoma. Conducted at the People's Hospital of Guangxi Zhuang Autonomous Region, the study included patients treated between January 2020 and June 2022. Participants were divided into two groups: an experimental group receiving Thymosin Alpha-1 alongside lenvatinib and sintilimab, and a control group receiving only lenvatinib and sintilimab. The primary endpoints evaluated were overall survival and progression-free survival, with tumor responses assessed using mRECIST criteria.

 Why it matters for Thymosin Alpha-1 research

The results of this study are significant for ongoing research into Thymosin Alpha-1, particularly in the context of hepatocellular carcinoma, which presents a major treatment challenge due to its aggressive nature and poor prognosis. The combination of Thymosin Alpha-1 with established therapies like lenvatinib and sintilimab suggests a synergistic effect that may enhance patient outcomes. This finding could pave the way for further investigations into the mechanisms by which Thymosin Alpha-1 modulates immune responses and tumor dynamics.

 Key findings

The median overall survival for patients receiving Thymosin Alpha-1 was 16 months, compared to 11 months for the control group.

The median progression-free survival was 7 months for the experimental group versus 4 months for the control group.

The objective response rate in the experimental group was 55.8%, while the control group had a rate of 34.7%.

The disease control rate was 76.7% in the experimental group compared to 59.2% in the control group.

No significant differences were observed in the incidence of grade 1-2 or grade 3-4 adverse events between the two groups.

The study supports the safety and efficacy of Thymosin Alpha-1 in combination with lenvatinib and sintilimab for treating unresectable hepatocellular carcinoma.

 How Thymosin Alpha-1 works (background)

Thymosin Alpha-1 is a peptide that plays a crucial role in immune modulation. It is known to enhance the activity of T cells and natural killer (NK) cells, which are vital components of the immune response against tumors. By promoting the differentiation and proliferation of immune cells, Thymosin Alpha-1 may help the body mount a more effective defense against cancer cells. Additionally, its potential to improve the efficacy of other therapeutic agents makes it a valuable candidate for combination therapies in oncology.

 Practical takeaways for researchers

For researchers investigating Thymosin Alpha-1, this study highlights the importance of exploring combination therapies in cancer treatment. The promising results regarding overall and progression-free survival suggest that Thymosin Alpha-1 could be integrated into treatment protocols for unresectable hepatocellular carcinoma. Future research should focus on understanding the underlying mechanisms of action, optimal dosing strategies, and the potential for Thymosin Alpha-1 in other malignancies. Researchers are encouraged to consider the implications of these findings in the broader context of peptide therapy and immuno-oncology.

 FAQ

 What is Thymosin Alpha-1?

Thymosin Alpha-1 is a peptide that modulates immune responses and has been studied for its potential in cancer therapy.

 How does Thymosin Alpha-1 work in cancer treatment?

It enhances the activity of immune cells, particularly T cells and NK cells, which can improve the body’s ability to fight tumors.

 What are the safety profiles of Thymosin Alpha-1 in clinical studies?

Clinical studies, including the recent one on hepatocellular carcinoma, indicate that Thymosin Alpha-1 has a favorable safety profile with no significant increase in severe adverse events when combined with other therapies.

 Source: PubMed · Sci Rep · published 2025-04-22.

## Sources

- PubMed · Sci Rep: https://pubmed.ncbi.nlm.nih.gov/40263352/